within Pharmacolibrary.Drugs.L_AntineoplasticAndImmunomodulatingAgents.L01D_CytotoxicAntibioticsAndRelatedSubstances.L01DA01_Dactinomycin;

model Dactinomycin
  extends Pharmacolibrary.Drugs.ATC.L.L01DA01;

  annotation (Documentation(
info       = "<html><body><table><tr><td>Drug:</td><td>L01DA01</td></tr><td>route:</td><td>intravenous</td></tr><tr><td>n-compartments</td><td>2</td></tr></table><p>Dactinomycin (also known as actinomycin D) is a cytotoxic antibiotic used mainly as an antineoplastic agent. It is approved for use in the treatment of various cancers, including Wilms tumor, rhabdomyosarcoma, Ewing's sarcoma, and gestational trophoblastic neoplasia. It works by binding to DNA and inhibiting RNA synthesis, thus preventing cell replication.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters reported in adult cancer patients following intravenous bolus administration. Data primarily from clinical studies in adult and paediatric patient populations with various solid tumors.</p><h4>References</h4><ol><li><p>Veal, GJ, et al., &amp; Boddy, AV (2005). Pharmacokinetics of dactinomycin in a pediatric patient population: a United Kingdom Children&#x27;s Cancer Study Group Study. <i>Clinical cancer research : an official journal of the American Association for Cancer Research</i> 11(16) 5893–5899. DOI:<a href=\"https://doi.org/10.1158/1078-0432.CCR-04-2546\">10.1158/1078-0432.CCR-04-2546</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/16115931/\">https://pubmed.ncbi.nlm.nih.gov/16115931</a></p></li><li><p>Tattersall, MH, et al., &amp; Frei, E (1975). Pharmacokinetics of actinoymcin D in patients with malignant melanoma. <i>Clinical pharmacology and therapeutics</i> 17(6) 701–708. DOI:<a href=\"https://doi.org/10.1002/cpt1975176701\">10.1002/cpt1975176701</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/1139861/\">https://pubmed.ncbi.nlm.nih.gov/1139861</a></p></li><li><p>Couvreur, P, et al., &amp; Speiser, P (1980). Tissue distribution of antitumor drugs associated with polyalkylcyanoacrylate nanoparticles. <i>Journal of pharmaceutical sciences</i> 69(2) 199–202. DOI:<a href=\"https://doi.org/10.1002/jps.2600690222\">10.1002/jps.2600690222</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/7359324/\">https://pubmed.ncbi.nlm.nih.gov/7359324</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
end Dactinomycin;
